Aduro's ADU-214
Oct 04, 2018
Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner
Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 Million Hologic, a global champion of women's health based in Massachusetts, United States, is taking possession of Focal Therapeutics, a medical device company, for USD 125 million to complement its breast-conserving surgery permit...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
